

Special Issue

New Strategies in the Treatment of Thyroid Carcinoma

Message from the Guest Editor

The new millennium has marked the beginning of individualized therapeutic approaches in cancer treatments. Cancer is not a single disease. The new paradigm in the management of thyroid cancer involves molecular and nuclear theranostics. Under this umbrella, we place a number of small molecules for targeted therapy, slight differences in modes of action producing substantial differences in therapeutic impact. The molecular theranostics concept not only directly influences RAI theranostics, but also initial and subsequent surgical interventions. RAI is the epitome of theranostics; however, the theranostics power of RAI is substantially depressed due to the genetic and epigenetic aberrations in cancer cells involving the expressions and functions of specific molecules. This Special Issue of the *JCM* will review the evolving role of molecular therapies in the context of theranostics value in thyroid cancer. Special emphasis will be given to MAPK pathway modulation as a novel therapeutic strategy, the new techniques and approaches in RAI treatment, and, in lieu of molecular innovations, the changes in surgical treatment philosophy.

Guest Editor

Prof. Dr. Seza Ali Gulec

1. HCA Florida, Aventura Hospital, Miami, FL, USA
2. Miami Cancer Research Center, Miami, FL, USA
3. Florida International University Herbert Wertheim College of Medicine, Miami, FL, USA

Deadline for manuscript submissions

closed (15 February 2024)



Journal of Clinical Medicine

an Open Access Journal
by MDPI

Impact Factor 3.0
CiteScore 5.7
Indexed in PubMed



mdpi.com/si/170517

Journal of Clinical Medicine
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
jcm@mdpi.com

[mdpi.com/journal/
jcm](https://mdpi.com/journal/jcm)





Journal of Clinical Medicine

an Open Access Journal
by MDPI

Impact Factor 3.0
CiteScore 5.7
Indexed in PubMed



[mdpi.com/journal/](https://mdpi.com/journal/jcm)

[jcm](https://mdpi.com/journal/jcm)



About the Journal

Message from the Editorial Board

There has been an explosion of gene and target based research and therapeutics in the multitude of fields that compose clinical medicine. The *Journal of Clinical Medicine's* (JCM) staff and editorial board are dedicated to providing cutting edge, timely, and peer-reviewed articles covering the diverse subspecialties of clinical medicine. The journal publishes concise, innovative, and exciting research articles as well as clinically significant articles and reviews that are pertinent to the myriad of disciplines within medicine. The articles published are relevant to both primary care physicians and specialists. The journal's full-texts are archived in PubMed Central and indexed in PubMed. Please consider submitting your manuscripts for publication to our journal and check us out on-line!

Editors-in-Chief

Prof. Dr. Emmanuel Andr  s

Internal Medicine Department, University Hospital Strasbourg, 67000
Strasbourg, France

Prof. Dr. Kent Doi

Department of Acute Care Medicine, University of Tokyo, Tokyo, Japan

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Medicine, General and Internal) / CiteScore - Q1 (General Medicine)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 16 days after submission; acceptance to publication is undertaken in 2.6 days (median values for papers published in this journal in the second half of 2024).